Live Quote · NASDAQDNLIHealthcare· Biotechnology

Denali Therapeutics Inc.

$25.83 0.58%($-0.15)
TickerSpark Score
57/100
Mixed
67
Valuation
20
Profitability
15
Growth
84
Health
100
Momentum

Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a DNLI research report →

52-Week Range93% of range
Low
$12.58
Current
$25.83
High
$26.80

About the company

Denali Therapeutics Inc. is a biopharmaceutical firm, founded in 2013 and based in South San Francisco, California, which focuses on identifying and advancing treatments for neurodegenerative conditions within the United States. The company, initially known as SPR Pharma Inc.

CEO
Ryan J. Watts
IPO
2017
Employees
443
HQ
South San Francisco, CA, US

Price Chart

+73.36% · this period
$25.98$19.37$12.75Jul 02Dec 31Jul 02
Valuation
Market Cap
$4.10B
P/E
-8.97
P/S
0.00
P/B
5.21
EV/EBITDA
-7.60
Div Yield
0.00%
Profitability
Gross Margin
0.00%
Op Margin
0.00%
Net Margin
0.00%
ROE
-52.20%
ROIC
-46.93%
Growth & Income
Revenue
$0 · 0.00%
Net Income
$-512,540,000 · -21.23%
EPS
$-2.97 · -15.56%
Op Income
$-555,342,000
FCF YoY
-16.09%
Performance & Tape
52W High
$26.80
52W Low
$12.58
50D MA
$20.91
200D MA
$18.84
Beta
1.01
Avg Volume
1.80M

Get TickerSpark's AI analysis on DNLI

Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.

Get Pro Access →

Already have an account? Log in

Form 4 · Filings

Recent insider transactions

Who's buying, who's selling, and how much.

DateInsiderTypeShares
Jun 3, 26FLATLEY JAY Tother6,408
Jun 3, 26FLATLEY JAY Tother19,226
Jun 3, 26Klein Peter Sother6,408
Jun 3, 26Klein Peter Sother19,226
Jun 3, 26Krognes Steve E.other6,408
Jun 3, 26Krognes Steve E.other19,226
Jun 3, 26Schenkein David Pother6,408
Jun 3, 26Schenkein David Pother19,226
Jun 3, 26Thornberry Nancyother6,408
Jun 3, 26Thornberry Nancyother19,226
Coverage · DNLI

Our DNLI coverage

Recent articles, reports, and earnings notes.

On-Demand Research

No research on DNLI yet

For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.

Generate DNLI report →
Internal Compare

Similar companies

Peers in the same neighborhood.